Cabozantinib is a multi-target tyrosine kinase inhibitor with activity against MET, VEGFR, AXL and RET, used in advanced renal cell carcinoma, hepatocellular carcinoma and medullary thyroid cancer. Simson Pharma's Cabozantinib reference standard and impurities support stability-indicating method development for this broad-spectrum kinase inhibitor.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cabozantinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.